Clinical Effects of Topiroxostat on Renal and Endothelial Function in A Patient with Chronic Kidney Disease and Hyperuricemic Arteriolopathy: A Case Report.

Abstract

Hyperuricemia is associated with the progression of chronic kidney disease (CKD) and cardiovascular diseases. Topiroxostat, a selective xanthine oxidase inhibitor, effectively reduces serum uric acid (UA) levels and urinary albumin excretion (UAE) in CKD patients. A 50-year-old Japanese man was referred to our hospital due to albuminuria and hyperuricemia, and renal biopsy showed a typical hyperuricemic arteriolopathy. Treatment with topiroxostat decreased serum UA levels (9.2 mg/dL at baseline to 6.4 mg/dL after 6 months), UAE (388 to 88 mg/g.cr), and urinary level of liver-type fatty acid-binding protein (28.8 to 19.8 µg/g.cr). Interestingly, topiroxostat treatment was associated with a trend towards improved flow-mediated dilation (5.4 to 5.8%). These results suggested that topiroxostat in CKD patients with hyperuricemia is potentially effective, not only for ameliorating renal damages but also for improving endothelial function beyond its UA-lowering action.

• Authors: Atsushi Tanaka, Tsukasa Nakamura, Eiichi Sato, Koichi Node
• Journal: Drugs in R&D (Drugs R D) Vol. 17 Issue 1 Pg. 97-101 (Mar 2017) ISSN: 1179-6901 [Electronic] New Zealand
• PMID: 28074335 (Publication Type: Case Reports, Journal Article)

Chemical References

• Nitriles
• Pyridines
• FYX-051

Topics

• Humans
• Hyperuricemia (drug therapy)
• Male
• Middle Aged
• Nitriles (administration & dosage, therapeutic use)
• Pyridines (administration & dosage, therapeutic use)
• Renal Insufficiency, Chronic (drug therapy)